Please login to the form below

Not currently logged in
Email:
Password:

OFT report praised by EAASM chairman

The chairman of the European Alliance for Access to Safe Medicines, Jim Thomson, welcomes the findings of the OFT report on direct-to-pharmacy supply models adopted by a number of pharmaceutical companies

The chairman of the European Alliance for Access to Safe Medicines (EAASM), Jim Thomson, has welcomed the findings of the Office of Fair Trading (OFT) report regarding direct-to-pharmacy (DTP) supply models adopted by a number of pharmaceutical companies.

Thomson said: "I welcome the OFT findings. I think them extremely fair. It is essential that fair prices are maintained and that supply is assured. The OFT has struck a blow for patients. Indeed, it has struck two. It has warned of the risks of badly implemented DTP, while identifying the benefits of DTP."

"I also applaud the OFT for championing this concern and for recommending on behalf of patients measures to protect against it. That said, to assume that DTP is about pricing alone is to completely miss the point. What DTP does is add security to the supply chain. This is the security that patients deserve doctors crave. One of the less publicised findings from the recent MORI/MHRA surveys is that doctors are tremendously concerned about counterfeits," concluded Thomson.

The OFT report said that direct-to-pharmacy (DTP) models adopted by pharmaceutical companies may carry a "significant risk" of higher costs to the NHS.

The OFT report focuses on the implementation of a supply arrangement between Pfizer and UniChem, the wholesale business of Alliance Boots, which had caused widespread concern in the industry earlier in 2007. The company sells the drugs directly to pharmacies and pays UniChem a set fee to deliver them. Medicines are normally distributed through a network of wholesalers, competing to supply pharmacists at discounted prices.

The OFT has made several recommendations as to how the government could deal with the issue in its Pharmaceutical Price Regulation Scheme (PPRS) negotiations, including reducing the list prices of drugs by an amount equivalent to the average discounts received by pharmacies.

The OFT has not discounted action under the Competition Act should competition issues arise from drug manufacturers using too few wholesalers.

12th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics